Tim Lugo
Stock Analyst at William Blair
(0.49)
# 4,113
Out of 5,006 analysts
22
Total ratings
35.71%
Success rate
-25.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Lugo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | n/a | $54.70 | - | 3 | Oct 30, 2024 | |
| APLT Applied Therapeutics | Initiates: Outperform | n/a | $1.07 | - | 1 | Jul 31, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | n/a | $46.94 | - | 1 | Apr 15, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $40 | $5.52 | +624.64% | 1 | Mar 28, 2024 | |
| ZVRA Zevra Therapeutics | Initiates: Outperform | n/a | $10.19 | - | 1 | Mar 12, 2024 | |
| ABBV AbbVie | Upgrades: Outperform | n/a | $232.83 | - | 2 | Jan 29, 2024 | |
| ACRS Aclaris Therapeutics | Downgrades: Market Perform | n/a | $1.84 | - | 1 | Nov 13, 2023 | |
| TVTX Travere Therapeutics | Downgrades: Market Perform | n/a | $25.50 | - | 1 | Sep 21, 2023 | |
| SPRY ARS Pharmaceuticals | Downgrades: Market Perform | n/a | $10.33 | - | 2 | Sep 20, 2023 | |
| VTGN Vistagen Therapeutics | Downgrades: Market Perform | n/a | $3.96 | - | 3 | Jul 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.99 | - | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $39.11 | - | 1 | Jan 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.05 | - | 2 | Sep 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.67 | - | 1 | May 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $46 | $15.02 | +206.26% | 1 | May 30, 2017 |
BioMarin Pharmaceutical
Oct 30, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $54.70
Upside: -
Applied Therapeutics
Jul 31, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.07
Upside: -
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $46.94
Upside: -
Solid Biosciences
Mar 28, 2024
Initiates: Outperform
Price Target: $40
Current: $5.52
Upside: +624.64%
Zevra Therapeutics
Mar 12, 2024
Initiates: Outperform
Price Target: n/a
Current: $10.19
Upside: -
AbbVie
Jan 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $232.83
Upside: -
Aclaris Therapeutics
Nov 13, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.84
Upside: -
Travere Therapeutics
Sep 21, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $25.50
Upside: -
ARS Pharmaceuticals
Sep 20, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.33
Upside: -
Vistagen Therapeutics
Jul 22, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.96
Upside: -
Nov 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.99
Upside: -
Jan 8, 2020
Initiates: Outperform
Price Target: n/a
Current: $39.11
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.67
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: $46
Current: $15.02
Upside: +206.26%